DYRK1A and Dravet syndrome: This compound, able to restore the proliferative capacity of NSCs derived from DS model mice, proved to inhibit DYRK1A in the mid-nanomolar range (IC50 = 76.9 nM) without the promiscuity of 51 or side effects of 4 due to low inhibition of MAO-A (IC50 = 2273.91 μM).